Zetataxo Vial 300Mg with 1 Ampoule (Paclitaxel)

Category

Oncological

Line

Antineoplastic

Brand

Zetataxo

Molecule

Paclitaxel

Presentation

300 mg vial with 1 ampoule

Laboratory

Glenmark

Indications

Zetataxo is indicated for the treatment of various types of cancer, including breast cancer, ovarian cancer, and non-small cell lung cancer. This medication works by inhibiting cell division, which results in the arrest of tumor growth. It can be used as adjuvant therapy or in palliative treatments, depending on the stage and extent of the disease. It is important that the use of Zetataxo is supervised by a physician specialized in oncology, who will evaluate the individual patient's situation and determine the appropriate treatment regimen.

Composition

Each vial of Zetataxo contains 300 mg of paclitaxel as the active ingredient. It also includes excipients that facilitate the formulation and administration of the medication.

Contraindications

Zetataxo is contraindicated in patients with known hypersensitivity to paclitaxel or any of the excipients in the formulation. Its use is not recommended in patients with severe neutropenia, acute severe infections, or those with conditions that may compromise the patient's health during treatment.

Precautions

Caution should be exercised when administering Zetataxo to patients with a history of heart disease, neuropathies, or those receiving concomitant treatments that may interact with paclitaxel. Constant medical monitoring is essential during treatment to detect possible adverse effects and adjust the dose if necessary.

Storage

Store in a cool, dry place, protected from light. Keep out of reach of children. Do not use after the expiry date indicated on the packaging.

Prescription required.

Consult your doctor.